Abstract
Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.
Similar content being viewed by others
References
Owen WF, Lew NL, Liu Y, Lowrie EG (1993) The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001–1006
Cheung KK, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK (2009) Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol 15(4):177–180
Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21(7):1395–1403
Rosen G, Caparros B, Huros AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma. Cancer 49:1221–1230
Thierry FX, Vernier I, Dueymes JM, Roche H, Canal P, Meens F, Pourrat JP, Conte JJ (1989) Acute renal failure after high dose MTX therapy. Nephron 51:416–417
Hande KR, Balow JE, Drake JC (1977) Methotrexate and haemodalyisis. Ann Intern Med 87:495–496
Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2006) Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. Am J Med Sci 332(3):156–158
Stoller RG, Kenneth RH, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 297:630–634
Feagan BG, Rochon J et al (1995) Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigations. N Engl J Med 332:292–297
Basile C, Montanaro A, Semeraro A (2002) Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transpl 17(3):530–531
Chess JA, Scholey G, Mikhail AI (2004) Neutropenia associated with the use of low-dose methotrexate in a peritoneal dialysis patient. Nephrol Dial Transpl 19(8):2158–2159
Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272–276
Ellman MH, Ginsberg D (1990) Low dose methotrexate and severe neutropaenia in patients undergoing renal dialysis. Arthritis Rheum 33:1060–1061
Clatham WW, Morgan SL, Alarcon GS (2000) Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum 43:1185–1186
Chester KA, Baker M, Mayer A (2005) Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol 1(4):549–559
Hammoudeh M (2006) Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford) 45:357–359
Gottenberg JE, Merle-Vincent F, Bentaberry F, Alanore Y, Berenbaum F, Fautrel B, Combe B, Durbarch A, Sibilia J, Dougados M, Mariette X (2003) Anti tumour necrosis factor a therapy in 15 patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 48:2019–2024
Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinouria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573
Hueber AJ, Tunc A, Schett G, Manger B (2007) Anti-tumour necrosis alpha therapy in patients with impaired renal function Ann. Rheum Dis 66:981–982
Nestorov I (2005) Clinical pharmacokinetics of tumour necrosis factor antagonists. J Rheumatol 32(74):13–18
Singh R, Cuchacovich R, Huang W, Espinoza LR. (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol 29 (3):636–637
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Hasani, H., Roussou, E. Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 31, 1545–1547 (2011). https://doi.org/10.1007/s00296-011-2041-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2041-5